Left ventricular global longitudinal strain is worse in BRCA mutation positive breast cancer patients prior to cancer treatment and premature menopause.
BRCA
Breast cancer
Cardiomyopathy
Cardiotoxicity
LV-GLS
Oophorectomy
Strain
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
04
12
2023
accepted:
10
04
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
8
5
2024
Statut:
aheadofprint
Résumé
Breast cancer patients with mutations in human tumor suppressor genes BRCA1 and BRCA2 are at higher risk of cardiovascular disease (CVD) than the general population, as they are frequently exposed to cardiotoxic chemotherapy, anti-estrogen therapy, radiation, and/or oophorectomy for cancer-related treatment and prophylaxis. Animal and cell culture models suggest that BRCA mutations may play an independent role in heart failure. We sought to evaluate cardiac structure and function in female BRCA1 and BRCA2 mutation carriers with breast cancer compared to BRCA wildtype women with breast cancer. We performed a 1:2 age- and hypertension-matched retrospective cohort study comparing BRCA1 and BRCA2 mutation carriers (n = 38) versus BRCA wildtype controls (n = 76) with a new diagnosis of breast cancer. Echocardiographic data were obtained within 6 months of breast cancer diagnosis and prior to chemotherapy, anti-estrogen therapy, radiation, or oophorectomy. Left ventricular global longitudinal strain (LV-GLS), a highly sensitive marker of LV function, was measured using QLab 15 (Philips Healthcare). In the total cohort of 114 patients with a new diagnosis of breast cancer, the median age was 45 ± 11 years and the prevalence of hypertension was 8%. There were no differences in traditional cardiovascular disease risk factors between cases and controls. BRCA carriers had lower LV-GLS (- 18.1% ± 4.7% vs. - 20.1% ± 3.8%, p = 0.02) and greater right atrial area (12.9 cm In women with newly diagnosed breast cancer and prior to treatment, LV-GLS was worse in BRCA1 and BRCA2 mutation carriers compared to those with BRCA wildtype. These findings suggest that BRCA mutations may be associated with subtle changes in cardiac function. Whether differences in GLS translate to increased cardiovascular risk in women with BRCA mutations needs to be further characterized.
Identifiants
pubmed: 38717528
doi: 10.1007/s10549-024-07344-4
pii: 10.1007/s10549-024-07344-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Gast KC et al (2018) Cardiovascular concerns in BRCA1 and BRCA2 mutation carriers. Curr Treat Options Cardiovasc Med 20(2):18
doi: 10.1007/s11936-018-0609-z
pubmed: 29497862
Sajjad M et al (2017) An exploratory study to determine whether BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity. Genes (Basel). https://doi.org/10.3390/genes8020059
doi: 10.3390/genes8020059
pubmed: 28157161
Jiang T et al (2016) Predictors of chemosensitivity in triple negative breast cancer: an integrated genomic analysis. PLoS Med 13(12):e1002193
doi: 10.1371/journal.pmed.1002193
pubmed: 27959926
pmcid: 5154510
De Talhouet S et al (2020) Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep 10(1):7073
doi: 10.1038/s41598-020-63759-1
pubmed: 32341426
pmcid: 7184602
Demissei BG et al (2022) BRCA1/2 mutations and cardiovascular function in breast cancer survivors. Front Cardiovasc Med 9:833171
doi: 10.3389/fcvm.2022.833171
pubmed: 35242827
pmcid: 8885808
Pearson EJ et al (2017) The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy. Breast Cancer Res Treat 162(1):59–67
doi: 10.1007/s10549-016-4101-8
pubmed: 28066861
Barac A et al (2016) Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. Breast Cancer Res Treat 155(2):285–293
doi: 10.1007/s10549-016-3678-2
pubmed: 26749359
Wellons M et al (2012) Early menopause predicts future coronary heart disease and stroke: the multi-ethnic study of atherosclerosis. Menopause 19(10):1081–1087
doi: 10.1097/gme.0b013e3182517bd0
pubmed: 22692332
pmcid: 3443540
Singh KK et al (2013) Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1. J Thorac Cardiovasc Surg 146(3):702–709
doi: 10.1016/j.jtcvs.2012.12.046
pubmed: 23317938
Shukla PC et al (2011) BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun 2:593
doi: 10.1038/ncomms1601
pubmed: 22186889
Lovren F et al (2014) BRCA1 shields vascular smooth muscle cells from oxidative stress. J Thorac Cardiovasc Surg 147(6):1946–1955
doi: 10.1016/j.jtcvs.2013.09.060
pubmed: 24239235
Singh S et al (2020) Breast cancer susceptibility gene 2 deficiency exacerbates oxidized LDL-induced DNA damage and endothelial apoptosis. Physiol Rep 8(13):e14481
doi: 10.14814/phy2.14481
pubmed: 32638521
pmcid: 7340845
Oliverio A et al (2020) BRCA1/2 variants and metabolic factors: results from a cohort of italian female carriers. Cancers (Basel). https://doi.org/10.3390/cancers12123584
doi: 10.3390/cancers12123584
pubmed: 33322597
Ivanov O et al (2018) Metabolic status of BRCA1 mutation carriers. J Clin Oncol 36:e12545
doi: 10.1200/JCO.2018.36.15_suppl.e12545
van der Kolk DM et al (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 124(3):643–651
doi: 10.1007/s10549-010-0805-3
pubmed: 20204502
Conrad N et al (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391(10120):572–580
doi: 10.1016/S0140-6736(17)32520-5
pubmed: 29174292
pmcid: 5814791
Wideqvist M et al (2022) Ten year age- and sex-specific temporal trends in incidence and prevalence of heart failure in Vastra Gotaland. Swed ESC Heart Fail 9(6):3931–3941
doi: 10.1002/ehf2.14103
Tsao CW et al (2018) Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 6(8):678–685
doi: 10.1016/j.jchf.2018.03.006
pubmed: 30007560
pmcid: 6076350
Lyon AR et al (2022) ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology And Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229–4361
doi: 10.1093/eurheartj/ehac244
pubmed: 36017568
Lang RM et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular imaging. J Am Soc Echocardiogr 28(1):1–39
doi: 10.1016/j.echo.2014.10.003
pubmed: 25559473
Farsalinos KE et al (2015) Head-to-Head comparison of global longitudinal strain measurements among nine different vendors: the EACVI/ASE inter-vendor comparison study. J Am Soc Echocardiogr 28(10):1171–1181
doi: 10.1016/j.echo.2015.06.011
pubmed: 26209911
Haji K, Marwick TH (2021) Clinical utility of echocardiographic strain and strain rate measurements. Curr Cardiol Rep 23(3):18
doi: 10.1007/s11886-021-01444-z
pubmed: 33594493
Cocco LD et al (2022) Global longitudinal strain for the early detection of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol) 34(8):514–525
doi: 10.1016/j.clon.2022.05.001
pubmed: 35637075
Nyberg J et al (2023) Echocardiographic reference ranges of global longitudinal strain for all cardiac chambers using guideline-directed dedicated views. JACC: Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2023.08.011
doi: 10.1016/j.jcmg.2023.08.011
pubmed: 37921718
Kosmala W, Jellis CL, Marwick TH (2015) Exercise limitation associated with asymptomatic left ventricular impairment: analogy with stage B heart failure. J Am Coll Cardiol 65(3):257–266
doi: 10.1016/j.jacc.2014.10.044
pubmed: 25533754
Picard MH et al (2011) American society of echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr 24(1):1–10
doi: 10.1016/j.echo.2010.11.006
pubmed: 21172594
Voigt JU et al (2015) Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/industry task force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging 16(1):1–11
doi: 10.1093/ehjci/jeu184
pubmed: 25525063
Grunig E et al (2013) Reference values for and determinants of right atrial area in healthy adults by 2-dimensional echocardiography. Circ Cardiovasc Imaging 6(1):117–124
doi: 10.1161/CIRCIMAGING.112.978031
pubmed: 23197080
Skaarup KG et al (2020) The impact of cardiovascular risk factors on global longitudinal strain over a decade in the general population: the Copenhagen city heart study. Int J Cardiovasc Imaging 36(10):1907–1916
doi: 10.1007/s10554-020-01906-5
pubmed: 32507994
Nakai H et al (2009) Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr 10(8):926–932
doi: 10.1093/ejechocard/jep097
pubmed: 19622532
Zoroufian A et al (2014) Evaluation of subclinical left ventricular dysfunction in diabetic patients: longitudinal strain velocities and left ventricular dyssynchrony by two-dimensional speckle tracking echocardiography study. Echocardiography 31(4):456–463
doi: 10.1111/echo.12389
pubmed: 24134395
Almeida AL et al (2014) Metabolic syndrome, strain, and reduced myocardial function: multi-ethnic study of atherosclerosis. Arq Bras Cardiol 102(4):327–335
pubmed: 24844874
pmcid: 4028951
Bianco CM et al (2020) Myocardial mechanics in patients with normal LVEF and diastolic dysfunction. JACC Cardiovasc Imaging 13(1 Pt 2):258–271
doi: 10.1016/j.jcmg.2018.12.035
pubmed: 31202770
Oikonomou EK et al (2019) Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol 4(10):1007–1018
doi: 10.1001/jamacardio.2019.2952
pubmed: 31433450
pmcid: 6705141
Narayan HK et al (2016) Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction. JACC Cardiovasc Imaging 9(10):1131–1141
doi: 10.1016/j.jcmg.2015.11.024
pubmed: 27085442
pmcid: 5055405
Singh KK et al (2012) BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure. J Biol Chem 287(9):6604–6614
doi: 10.1074/jbc.M111.292664
pubmed: 22157755
Witberg G et al (2019) Vascular endothelium function among male carriers of BRCA 1&2 germline mutation. Oncotarget 10(49):5041–5051
doi: 10.18632/oncotarget.27118
pubmed: 31489114
pmcid: 6707947
Nozynski JK et al (2016) BRCA1 reflects myocardial adverse remodeling in idiopathic dilated cardiomyopathy. Transplant Proc 48(5):1746–1750
doi: 10.1016/j.transproceed.2015.12.141
pubmed: 27496484
Mai PL et al (2009) Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS ONE 4(3):e4812
doi: 10.1371/journal.pone.0004812
pubmed: 19277124
pmcid: 2652075
Pasanisi P et al (2018) A dietary intervention to lower serum levels of IGF-I in BRCA mutation carriers. Cancers (Basel). https://doi.org/10.3390/cancers10090309
doi: 10.3390/cancers10090309
pubmed: 30181513